S
Stephen M. W. Chang
Researcher at Chiron Corporation
Publications - 36
Citations - 1859
Stephen M. W. Chang is an academic researcher from Chiron Corporation. The author has contributed to research in topics: Recombinant DNA & Alphavirus. The author has an hindex of 17, co-authored 36 publications receiving 1851 citations. Previous affiliations of Stephen M. W. Chang include Novartis & Oxford BioMedica.
Papers
More filters
Patent
Recombinant retroviruses delivering vector constructs to target cells
Jack R. Barber,Sunil Chada,Stephen M. W. Chang,Harry E. Gruber,Douglas J. Jolly,Paul K. Laikind,James G. Respess,Daniel C. St. Louis,John F. Warner +8 more
TL;DR: In this paper, the recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed.
Patent
Eukaryotic layered vector initiation systems
Thomas W. Dubensky,John M. Polo,Carlos E. Ibanez,Stephen M. W. Chang,Douglas J. Jolly,David A. Driver,Barbara A. Belli +6 more
TL;DR: In this paper, compositions and methods for making and utilizing eukaryotic layered vector initiation systems are presented, as well as methods for utilizing recombinant alphavirus vectors and their applications.
Journal ArticleDOI
DNA Immunization against Herpes Simplex Virus: Enhanced Efficacy Using a Sindbis Virus-Based Vector
Mangala J. Hariharan,David A. Driver,Kay Townsend,Duane Brumm,John M. Polo,Barbara A. Belli,Donald J. Catton,David Chi-Tang Hsu,Denise Mittelstaedt,James E. McCormack,Linda Karavodin,Thomas W. Dubensky,Stephen M. W. Chang,Theresa A. Banks +13 more
TL;DR: The in vivo efficacy of the Sindbis virus-based pSIN vectors as DNA vaccines and the potential usefulness of alphavirus-based vectors for DNA immunization in general and more specifically as a herpes simplex virus vaccine are demonstrated.
Journal ArticleDOI
Stable alphavirus packaging cell lines for Sindbis virus- and Semliki Forest virus-derived vectors
John M. Polo,Barbara A. Belli,David A. Driver,Ilya Frolov,Scott Sherrill,Mangala J. Hariharan,Kay Townsend,Silvia Perri,Steven J. Mento,Douglas J. Jolly,Stephen M. W. Chang,Sondra Schlesinger,Thomas W. Dubensky +12 more
TL;DR: Vector particle seed stocks could be amplified after low multiplicity of infection of PCLs, again without generating replication-competent virus, suggesting utility for production of large-scale vector preparations.